Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BCDA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Biocardia Inc

BCDA
Current price
2.02 USD -0.08 USD (-3.81%)
Last closed 2.08 USD
ISIN US09060U5074
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 10 925 347 USD
Yield for 12 month -28.62 %
1Y
3Y
5Y
10Y
15Y
BCDA
21.11.2021 - 28.11.2021

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California. Address: 320 Soquel Way, Sunnyvale, CA, United States, 94085

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.00 USD

P/E ratio

Dividend Yield

Financials BCDA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+58 000 USD

Last Year

+477 000 USD

Current Quarter

Last Quarter

-58 000 USD

Current Year

-4 329 000 USD

Last Year

-7 249 000 USD

Current Quarter

Last Quarter

-110 000 USD
EBITDA -8 392 000 USD
Operating Margin TTM -281 733.35 %
Price to Earnings
Return On Assets TTM -218.06 %
PEG Ratio
Return On Equity TTM -737.89 %
Wall Street Target Price 6.00 USD
Revenue TTM 3 000 USD
Book Value -0.33 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -4 673 000 USD
Earnings per share -2.14 USD
Diluted Eps TTM -2.14 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3 626.04
Price Sales TTM 3 659.04
Enterprise Value EBITDA -3.16
Price Book MRQ 10.67

Technical indicators BCDA

For 52 weeks

1.63 USD 4.66 USD
50 Day MA 2.25 USD
Shares Short Prior Month 68 607
200 Day MA 2.39 USD
Short Ratio 0.27
Shares Short 23 060
Short Percent 0.50 %